Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

01/04/2016 - 1 minute

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based.

City: Milan (Italy)

Founded: 1996

Employees: (+/-) 120 (as of 12/2015)

Financial Data: €13.52M Revenues (in 2015)

CEO: Riccardo Palmisano



Mission: MolMed is active in the development, research and clinical validation of novel antitumour therapies. On their pipeline you have two major novel therapeutics in current clinical development: TK, a ex vivo cell therapy, enabling safe HSCT from partially compatible haplo-identical donors (e.g close relatives i.e mother, father, brothers or sisters), who are available for most of all patients and NGR-hTNF, a novel vascular targeting agent, in Phase II in four different indications: colorectal,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member